FAQ on Quantum BioPharma Ltd.'s PET Tracer for Monitoring Myelin Integrity in Multiple Sclerosis
Summary
Quantum BioPharma Ltd. announced a PET tracer, developed in collaboration with Massachusetts General Hospital, shows potential for monitoring myelin integrity in MS patients, offering a new tool for evaluating the effectiveness of treatments like their investigational drug, Lucid-MS.
What is the significance of Quantum BioPharma’s PET tracer in multiple sclerosis research?
The PET tracer, [18F]3F4AP, can detect differences across MS lesions not visible on conventional MRI, serving as a potential biomarker for monitoring myelin integrity, demyelination, and treatment response.
How does Quantum BioPharma plan to use this PET tracer?
Quantum BioPharma aims to apply this imaging technology to evaluate its investigational neuroprotective drug, Lucid-21-302 (Lucid-MS), designed to protect the myelin sheath in MS.
Who developed the PET tracer mentioned in the study?
The tracer, [18F]3F4AP, was developed by Dr. Pedro Brugarolas from Massachusetts General Hospital.
Where was the study on the PET tracer published?
The study was published in the European Journal of Nuclear Medicine and Molecular Imaging on August 5, 2025.
What is Lucid-MS?
Lucid-MS is Quantum BioPharma’s patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
How can investors stay updated on Quantum BioPharma’s developments?
Investors can find the latest news and updates relating to QNTM in the company’s newsroom at https://ibn.fm/QNTM.
What other areas does Quantum BioPharma focus on besides MS?
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.
What is unbuzzd(TM) and how is it related to Quantum BioPharma?
unbuzzd(TM) is a product invented by Quantum BioPharma, with its OTC version spun out to Unbuzzd Wellness Inc., where Quantum BioPharma retains a 20.10% ownership and receives royalty payments from sales.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 143832